Introduction
============

The human gut microbiota consists of about 1500 microbial species which constitute 10^12^ bacteria per gram of stool ([@B30]). The gastrointestinal microbiota of healthy human adults consists primarily of bacteria belonging to phyla *Firmicutes* and *Bacteroidetes*, and to a lesser extent to phyla *Actinobacteria* and *Proteobacteria* ([@B47]; [@B219]). Density and composition of microbiota varies along both the length of the gut and the cross-section ([@B130]; [@B193]). Changes in nutrients, availability of oxygen, and presence of immune effectors in local microenvironment determine species variation and abundance ([@B50]). The most dominant taxa have the highest stability in the gut ([@B115]). Rapidly dividing facultative anaerobes from *Lactobacillaceae* and *Enterobacteriaceae* dominate in small intestine, while saccharolytic representatives of *Bacteroidales* and *Clostridiales* orders are abundant in the large intestine ([@B50]; [@B193]). Mucin-utilizing species of *Akkermansia* and *Bacteroides* are followed by aerotolerant *Proteobacteria* and *Actinobacteria* in direction to the epithelium ([@B193]). *Proteobacteria* and *Firmicutes* are found in crypts and represent the stock for reseeding the colon because they are protected from the luminal flow ([@B193]). At least 50--60% of the bacterial genera from the intestinal microbiota of a healthy individual produce spores which facilitate both microbiota persistence and transmission ([@B30]). The majority of gut bacteria are transient populations which pass through the lumen of the lower GIT ([@B193]).

Composition of gut microbiota varies among individuals with geographic provenance, gender, age, diet, malnutrition, and intake of probiotics or antimicrobial agents ([@B139]; [@B73]; [@B135]; [@B109]; [@B115]; [@B178]). Alterations in the composition of the gut microbiota and reductions in microbial diversity lead to different disorders such as inflammatory conditions of the intestine (inflammatory bowel disease, irritable bowel syndrome, colorectal cancer) ([@B61]; [@B64]; [@B150]), type 2 diabetes, obesity, anorexia nervosa, forms of severe acute malnutrition, cardiovascular diseases (atherosclerosis, hypertension, heart failure) ([@B190]), neurobehavioral diseases (autism spectrum disorder, major depression) ([@B40]). The microbiota is increasingly recognized for its ability to maintain homeostasis in health and disease influencing host appetite, function of the nervous system and several complex host behaviors ([@B172]; [@B213]; [@B201]; [@B206]). A healthy gut microbiota can be defined by the presence of the various microbial species that enhance metabolism, resistance to infection and inflammation, prevention against cancer and autoimmunity.

Lactobacilli are historically considered as integral part of human intestinal microbiota. Today, a large body of evidence indicates that only a small number of *Lactobacillus* species are true autochthonous inhabitants of the mammalian intestinal tract and that most lactobacilli present are allochthonous members derived from food or oral cavity ([@B151]; [@B207]). *Lactobacillus* spp. content of fecal samples is characterized by temporal fluctuations and lack of stability ([@B208]; [@B202]). Attempts to divide lactobacilli into resident and transient ones are hardly legitimate since the style of nutrition significantly affects their contents in the intestine. Lactobacilli together with enterococci dominate in the duodenum and in the jejunum ([@B151]; [@B69]), although their absolute number increases along the intestine from duodenum to colon ([@B46]). However, they constitute only a minor fraction within the human adult fecal microbiota, i.e., around 0.01 to 0.6% of total bacterial counts ([@B72]; [@B119]).

Metagenomics widely used for study of gut microbiota is unable to detect bacteria at concentrations less than 10^5^ bacteria per gram ([@B95]). A culturing approach that uses high-throughput culture conditions in combination with matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry and 16S rRNA sequencing for taxonomic identification and referred to as culturomics has allowed significant increase in a number of bacteria discovered in human GIT including species known in humans but not in the gut, species previously considered unculturable as well as new species. Considerable part of them is represented by *Firmicutes* ([@B96]) including *Bacillus* species ([@B95]; [@B125]; [@B167]).

For a long time, the representatives of *Bacillus* genus, unlike the species of *Lactobacillus*, were not considered as a part of the normal intestinal microbiome. Being isolated from feces, *Bacillus* spp. as soil microorganisms were considered transient. Recent studies show that they are present in the GIT in the amounts significantly higher than what can be explained by their ingestion with food only. *Bacillus* spp. (*B. pumilus, B. licheniformis, B. clausii, B. subtilis, B. megaterium, B. mediterraneensis*, *B. thuringiensis*) have been isolated from the healthy human GIT, where they are well-adapted and are more colonizing than transient ([@B55]; [@B8]; [@B107]). In environment, the vegetative forms of *Bacillus* are present usually near decomposing plants and in their rhizosphere. In the soil they exist mainly in the form of spores, which germinate in the digestive tract of humans and animals. Germination of *Bacillus* spores in the human small intestine and transient colonization should be considered as a part of the life cycle of human-associated *Bacillus* species ([@B77]). In the GIT, spores not only germinate but also are formed again from vegetative cells during a time shorter than in the laboratory ([@B188]; [@B63]).

Thus, it can be concluded that GIT microbiota including *Bacillus* and *Lactobacillus* species undergoes constant dynamic change. In our opinion, distinguishing between the resident and transient intestinal inhabitants is less relevant issue compared to the study of molecular pool released by them. Most of bacteria absorbed in the body can supplement the gastrointestinal microbiome ([@B46]). The challenge of identifying the "spheres of influence" of the transient microbiota in the human body has not been solved, and has not even been formulated, with the exception of some aspects of the pathogen entry into the body. Its bottleneck is the lack of data on the complexes secreted by this microbiota, their components, functions and the interaction between components, namely, the composition and biological role of the secretome.

We consciously narrowed the spectrum of secretome producers observed here to two representatives of the *Bacilli* class, genera *Lactobacillus* and *Bacillus*, due to their wide distribution and high probability of entering the human body. The ingestion of microorganisms occurs with food, water and bacterial probiotics. Facultative aerobic bacilli represent a smaller proportion of the intestinal microbiota than anaerobic bacteria ([@B149]), but they actively influence the microbial community of GIT and also the whole organism thanks to the great diversity of secreted compounds. Our studies of biopsies taken during surgical intervention in patients with diagnosed colorectal cancer revealed the presence of *Bacilli* closely associated with intestinal epithelium, traditionally considered as transient ones ([@B179]). Since secretory components can be studied only in culturable microorganisms, the insufficiency of genomic analysis of intestinal microbiota and the transition to functional analysis became evident ([@B46]; [@B95]). In this regard, the identification, characterization, and elucidation of the functional role of the components secreted by the minority of the intestinal microbial community, namely representatives of the *Bacilli* class in GIT, is an actual task. The modern concept of a gut--brain axis ([@B121]) must be detailed and refined taking into account the spectra of compounds secreted by *Bacilli*, namely low- and high-molecular components of the secretome and EVs, which affect the whole body and shape human health.

Beneficial Effects of *Lactobacillus* and *Bacillus*
====================================================

Historically, species of *Lactobacillus* and *Bacillus* are found in the traditional fermented food products possessing beneficial properties for the intestinal function ([@B132]; [@B163]; [@B101]; [@B183]; [@B113]) and are widely used as components of commercially available probiotics: DE111 (Deerland Enzymes, United States), Enterogermina (Sanofi Winthrop, Italy), Biosubtyl (Biophar, Vietnam), Biosporin (Biopharma, Russia), BioSpora (Klaire Labs, United States), Blicheni and Zhengchangsheng (Northeast Pharmaceutical Group, China), GanedenBC 30 (Ganeden, United States), Lactobacterin (Microgen, Russia), HOWARU or DR20 (Danisco, United States), Yakult (Yakult, Japan), PCC (Probiomics, Australia). In food industry, lactobacilli are applied as starter cultures in the production of fermented milk products, cheese, sausages, bread, kimchi, pickles, and yogurts, the latter accounting for the largest share of sales ([@B66]; [@B189]). The administration of probiotics has been shown to favorably alter the intestinal microbiota balance, enhance intestinal integrity and motility, inhibit the growth of harmful bacteria and increase resistance to infections ([@B189]).

As a part of GIT microbiota *Bacilli* participate in metabolism of dietary components, xenobiotics and drugs helping to maintain intestinal homeostasis and host health ([@B86]; [@B157]). The beneficial effect of probiotics on GIT is mediated by influence on composition, diversity and function of the intestinal microbiota as well as whole human organism. Probiotics suppress pathogenic bacteria and favor beneficial ones via competition for nutrients, especially for shared limited resource like iron, competitive attachment to the epithelium, formation of substrates for growth, production of waste products and antimicrobial compounds, strengthening of the barrier function of the epithelium, and modulation of innate immunity ([@B191]; [@B23]; [@B185]). For example, consumption of *B. coagulans* was shown to increase beneficial groups of bacteria in the gut of 65--80 years old humans and production of anti-inflammatory cytokines ([@B134]).

The efficacy of *Lactobacillus* and *Bacillus* in the prevention and/or treatment of intestinal diseases such as diarrhea, colitis, irritable bowel syndrome, irritable bowel disease, and colorectal cancer was demonstrated ([@B33]; [@B164]; [@B148]; [@B144]; [@B65]; [@B197]; [@B38]; [@B120]; [@B111]; [@B227]). In particular, treatment of colorectal colitis in mice with probiotic *B. subtilis* restored balance in gut microflora: beneficial species of *Bifidobacterium*, *Lactobacillus*, and *Butyricicoccus* spp. were increased, while gut damage-promoting species of *Acinetobacter* sp., *Ruminococcus* sp., *Clostridium* spp., and *Veillonella* sp. were decreased ([@B227]). *B. subtilis* also retained gut barrier integrity, decreased the endotoxin concentration and reduced gut inflammation ([@B227]; [@B20]). Sporulation of *B. subtilis* plays a major role in the development of GALT -- gut lymphoid tissue associated with the gastrointestinal mucosa - and in the diversity of the primary antibody population ("preimmune" repertoire) in rabbits ([@B153]). *Bacillus* spp. like other strains isolated from human stool were able to bind the human norovirus strains, the cause of acute viral gastroenteritis and foodborne diseases, around the outer cell surfaces and pili structures ([@B7]). The interaction between virus and bacteria is hypothesized to help the host immune system to better recognize infectious particles.

The ratio between the two major phyla inhabiting the human GIT, *Firmicutes* and *Bacteroidetes*, reflects the GIT status during the life and diseases. It is significantly decreased in infants and elderly individuals as compared to adults (0.4, 0.6, and 10.9, respectively) ([@B114]) and lowers upon antibiotic-associated diarrhea, coeliac disease, Crohn's disease, and ulcerative colitis ([@B138]; [@B139]; [@B34]; [@B147]). A decrease in populations of *Ruminococcus* and *Lactobacillus* was observed in a rat model of colorectal cancer ([@B230]). Microbial content of the patients with diagnosed colorectal cancer and healthy individuals differed significantly. *Firmicutes* and *Fusobacteria* were over-represented whereas *Proteobacteria* were under-represented in patients. In addition, *Lactococcus* and *Fusobacterium* exhibited a relatively higher abundance while *Pseudomonas* and *Escherichia--Shigella* were reduced in cancerous tissues compared to adjacent non-cancerous ones ([@B62]). *Bacilli* were shown to decrease quantitatively upon type 2 diabetes ([@B162]). The possibility of using probiotics in the therapy of diseases, namely allergy, asthma, diabetes, cardiovascular diseases is discussed ([@B53]).

Viability is by definition a prerequisite for probiotic effectiveness as it is essential for colonization of intestinal mucosa, displacement of pathogens and immunomodulation. Viable bacteria demonstrate adhesive and antagonistic properties and produce a large number of extracellular enzymes and biologically active compounds ([@B175]). Nevertheless, there is increasing evidence that isolated bacteria-derived molecules and surface components (e.g., cell wall components, cell wall associated proteins, S-layer proteins) potentiate probiotic benefits attributed earlier to viable probiotic bacteria ([@B97]; [@B158]).

Despite more than a century of active use of probiotics, initiated by I. Mechnikov in 1907, the majority of modern reviews assessing the effectiveness of these drugs confirm the need for further studies to determine the exact mechanisms of positive effects of probiotics on the human body. Both live probiotic bacterial cells and their metabolites can be useful in treatment of intestinal diseases ([@B136]). The molecular basis for the effectiveness of probiotics remains unexplored or only partially studied. The future study aimed at deciphering the mechanisms that determine the probiotic properties of bacteria will certainly allow expanding the areas of scientifically proven probiotic use in medicine.

Microbiota--Human Metabolic Interaction
=======================================

Between the gut microbiota and host organism there is an extremely complex relationship that affects the human metabolism, immunity and health ([@B112]). This crosstalk is mediated by nutrients, metabolites, antimicrobial compounds. It was demonstrated that the psychological and physical stress of a host affects its gut microbiota and, in turn, gut microflora can modulate host's mood and appetite ([@B161]). Gut microbiota is regulated by the host through production of non-specific antimicrobial peptides such as defensins ([@B128]), secreted IgA which provides the selection and the maintenance of the commensal bacteria ([@B59]), and miRNAs specifically regulating bacterial transcripts and affecting bacterial growth ([@B106]). It was proved that host genetic background affects the composition and function of the gut microbiota, altering the production of microbial metabolites and intestinal inflammation ([@B98]). For example, the microbiota of mice deficient in caspase recruitment domain family member 9 (*CARD9*) failed to metabolize tryptophan that increased host susceptibility to colitis ([@B98]).

Microbial species are recognized by host's immune system. Commensal bacteria have immunomodulatory properties that allow them inducing tolerogenic immune responses against themselves and contributing to host protective immune responses against pathogens ([@B20]; [@B67]; [@B173]). It is known that probiotics affect key signaling pathways, such as NFκB and MAPK, through the pattern-recognition receptors (TLR, NOD) ([@B23]) enhancing the production of anti-inflammatory cytokines ([@B134]) and reducing the emergence of proinflammatory ones ([@B166]). The gut microbiota is able to influence host antigen production by human monocyte-derived dendritic cell populations in a species-specific manner ([@B20]).

Gut microbiota affects host physiology by releasing bioactive metabolites including antibiotics, enzymes, vitamins and amino acids (choline, methionine, vitamin B), minerals (cobalt, iodine, selenium, and zinc) and energy metabolites (SAM, acetyl-CoA, NAD^+^, α-KG, and ATP), SCFAs (acetate, propionate, butyrate, caproate, and valerate), neurotransmitters \[acetylcholine, dopamine, noradrenaline, serotonin, and γ-aminobutyric acid (GABA)\], hormones, bacterial antigens, pathogen-associated molecular patterns, and toxins ([@B51]; [@B108]). These molecules enter host circulation thereby mediating the link between the gut and other organs (brain, lung, liver, muscle) ([@B177]) and modulate physiological pathways and even behavior ([@B201]; [@B206]). The influence of gut microbiota on the epigenetic regulation of host genes via DNA methylation and histone modifications has been demonstrated ([@B222]). Contact-independent metabolic exchange helps signal dispersal among neighboring cells as well as its blockage when needed.

Bacteria produce a lot of chemically diverse metabolites with poorly understood function. *Bacillus* species are among the most frequent producers of bioactive secondary metabolites (800 compounds), while lactobacilli produce 100s of compounds ([@B21]). Known to date, the results of the study of representatives of the *Bacilli* class colonizing the human GIT mostly refer to ascertaining their positive, less often negative, impact on the body. We tried to systematize the available knowledge about compounds and complexes produced by these bacteria which serve as effectors triggering certain processes in the body (**Figure [1](#F1){ref-type="fig"}**), and identify the stage responsible for actually registered "influence." *Bacilli* introduced into the GIT through the consumption of fermented food do integrate the resident microbiome ([@B46]) and contribute to its regulatory and health promoting action producing a variety of substances ranging from low molecular weight regulatory agents to proteins and peptides with antimicrobial and antitumor effects. Metabolites secreted by bacteria form a coat around the cells which contributes to nutrient supply, communication, and protection from damage caused by direct interaction with other species or their metabolites. Due to diffusion, the concentration of extracellular metabolites decreases with distance. To ensure that secreted components will reach their targets bacteria utilize membranous vesicles for their transportation.

![Compounds secreted by the representatives of *Lactobacillus* and *Bacillus* mediating their beneficial effects in the GIT. Top-appreciated compounds are shown in upper part of panels, under-appreciated compounds -- in lower parts. Both *Lactobacillus* and *Bacillus* are minor part of GIT microbiota. Of them, *Lactobacillus* spp. dominate quantitatively secreting a few compounds, while *Bacillus* spp. are less abundant but produce a variety of secreted substances with a wide spectrum of activities. Representatives of the *Bacilli* class were isolated from colon epithelia biopsy of the patients with diagnosed colorectal cancer. Atomic force microscopy images of *L. plantarum* (photo provided by Dr. *Dina Yarullina*) and *B. pumilus* (photo kindly provided by Dr. *Galina Yakovleva*) were obtained in air (contact mode) of stationary phase cells that were deposited on glass and dried prior analysis. Bacteria were identified using MALDI-TOF technique and 16S RNA sequencing. Representative AFM images show nanoscale structures on the cell surface and around the cells attributed to EVs.](fmicb-08-01666-g001){#F1}

Top-Appreciated Components of *Bacilli* Secretome
=================================================

It is well-appreciated that complex of **enzymes** (proteases, amylases, cellulases, lipases) secreted by *Bacilli* aid in digestion of food components in GIT ([@B90]; [@B89]). Bile salt hydrolases of lactobacilli reduce blood cholesterol and diminish the risk for cardiovascular diseases ([@B140]; [@B94]). Recently, an antagonistic role of *L. johnsonii* La1 extracellular bile salt hydrolase against intestinal protozoan parasite *Giardia duodenalis* was revealed ([@B192]). Other enzymes like *N*-acylated homoserine lactone (AHL)-lactonase help to modulate the microbiota content by decreasing the number of quorum-sensing pathogenic bacteria in the GIT through direct disruption of their signal molecules ([@B204]; [@B229]). Moreover, many enzymes are involved in the formation of metabolites which possess their own biological activities. For instance, during fermentation of milk and other proteinaceous products lactobacilli are able to release biologically active peptides with angiotensin I-converting enzyme (ACE)-inhibitory activity. Among these antihypertensive peptides β-casein-derived tripeptides (lactotripeptides) are most studied ([@B74]; [@B56]).

**Short-chain fatty acids** are formed upon dietary carbohydrates fermentation by both *Bacilli* genera, studied in this review. The most common SCFA is lactate followed by acetic, propionic, butyric acids and minor isobutyrate, 2-methylpropionate, valerate, isovalerate, hexanoate. SCFAs are one of the most important gut microbial products affecting a range of host processes including energy utilization, host--microbe signaling, and control of colonic pH. Decrease of a luminal pH creates an environment favoring beneficial species like *Faecalibacterium prausnitzii* and inappropriate for many others bacteria and yeasts ([@B134]). SCFAs positively influence the gut motility ([@B218]) and intestinal secretion ([@B24]), inhibit proliferation of tumor cells by apoptosis induction, stimulate production of insulin-like growth factor 1 promoting bone growth and remodeling ([@B216]), cause epigenetic modifications, regulate blood pressure and inflammation ([@B129]). The multifaceted roles of SCFAs nominate them for the key molecular link between diet, the microbiome and health.

Lactate produced by *Lactobacillus* provides an unfavorable environment for the growth of many pathogenic bacteria, it also acts as a permeabilizer of the Gram-negative bacterial outer membrane, thus increasing the susceptibility of pathogens to antimicrobial molecules, e.g., bacteriocins or host lysozyme ([@B5]). Strains of *B. licheniformis* and *B. coagulans* also ferment different sugars with formation of lactic acid ([@B209]; [@B134]). Butyrate is the local energy source for colonocytes ([@B100]); also it plays an important role in maintenance of the gut barrier function through stimulation of tight junction integrity and mucin production ([@B142]; [@B87]). The SCFAs produced by the human gut microbiota are transported from the gut lumen with the bloodstream to a variety of different organs, where they are used in lipid and energy metabolism, particularly by the hepatocyte cells of the liver, which use propionate for gluconeogenesis, whilst acetate and butyrate are mostly involved in lipid biosynthesis ([@B44]). Besides, SCFAs appear to exert regulatory effects on gluconeogenesis and lipogenesis mediated by peroxisome proliferator-activated receptor gamma (PPARγ) ([@B43]) and protein kinases, such as AMP-activated protein kinase ([@B142]; [@B43]) or mitogen-activated protein kinases (MAPK) ([@B87]). SCFAs have been reported to represent the natural ligands for free fatty acid receptors 2 and 3 (FFAR 2/3) (former G protein-coupled receptors, GPR43 and GPR41), involved in the regulation of lipid and glucose metabolism and found on a wide range of cell types, including enteroendocrine and immune cells ([@B45]). Moreover, as far as these receptors are expressed on neurons of the peripheral, autonomic and somatic nervous systems, SCFAs can modulate neuronal activity and visceral reflexes ([@B133]). SCFAs are considered as promising for the prevention and treatment of the metabolic syndrome, certain types of cancer, bowel disorders, such as ulcerative colitis, Crohn's disease, and antibiotic-associated diarrhea ([@B45]; [@B154]).

**Hydrogen peroxide (H~2~O~2~)** production by lactobacilli has been suggested to be a non-specific antimicrobial defense mechanism. *L. jensenii*, *L. crispatus, L. gasseri*, and *L. acidophilus* are the most common H~2~O~2~-producing lactobacilli inhabiting the human intestine and are often applied as probiotic supplements in the food industry ([@B116]; [@B75]). In gastrointestinal environment, SCFAs and bacteriocins have been considered as key antimicrobial factors, whereas the impact of H~2~O~2~ production remains underappreciated. However, H~2~O~2~, like other reactive oxygen species, exerts strong cytotoxicity against microorganisms. Although H~2~O~2~ itself is not highly reactive, it can readily diffuse across cellular membrane and through the Fenton reaction form highly reactive hydroxyl radicals, which cause oxidative damage to major biological macromolecules, e.g., oxidation of protein thiols, peroxidation of lipids, DNA base damage, and strand breakage of nucleic acids ([@B84]; [@B198]). The role for H~2~O~2~ in the anti-*Salmonella* activity of *L. johnsonii* NCC533, the human intestinal isolate and a probiotic strain, was revealed *in vitro* ([@B145]). *L. delbrueckii* VI1007 produces at least three growth-inhibiting factors, other than lactic acid, one of which has been identified as H~2~O~2~ ([@B200]). H~2~O~2~ may contribute to the maintenance of the normal microbiota. Especially for the vaginal microbiota, strong evidence exists that colonization with H~2~O~2~-producing lactobacilli is associated with lower rates of bacterial vaginosis and HIV acquisition ([@B212]; [@B14]). Moreover, H~2~O~2~ may exert immunomodulatory properties. It was showed that H~2~O~2~, produced by *L. crispatus* M247, acts as a signal transducing molecule activating peroxisome proliferator activated receptor γ (PPAR-γ), which plays a central role in regulation of intestinal inflammation and homeostasis ([@B205]). *L. johnsonii*-derived H~2~O~2~ has been shown to affect the activity of indoleamine 2,3-dioxygenase, an important immune modulator, both *in vitro* and in the rat model of type 1 diabetes ([@B199]).

**Poly P,** a linear polymer of over 700 phosphate residues, is synthesized by *Lactobacillus* with the help of polyphosphate kinase ([@B6]). It suppresses the oxidant-induced intestinal permeability inducing cytoprotective heat shock proteins in mouse small intestine through activation of integrin β1-p38 MAPK pathway ([@B165]). Poly P was shown to improve the inflammation grade and survival rate in mice model of colitis ([@B165]) and to inhibit viability of colon cancer cells via apoptosis through activation of the ERK pathway ([@B159]).

**Indole** derivatives formed from tryptophan by *Lactobacillus* cells act on the aryl hydrocarbon receptor in intestinal immune cells increasing IL-22 production which, in turns, beneficially impacts the immune system, enhances antifungal resistance and protection of mucosa from damage ([@B226]; [@B98]; [@B54]). The main inhibitory neurotransmitter in the brain, **GABA,** is produced with the help of glutamate decarboxylase expressed by multiple strains of *Lactobacillus* ([@B17]; [@B223]).

*Bacilli* synthesize B-group **vitamins** including folate and biotin during the fermentation of foods in GIT and can exchange them, thereby enabling the survival of organisms that do not synthesize those ([@B110]).

A number of **peptide and lipopeptide** **antibiotics and bacteriocins** are produced by *Bacilli* both involving ribosomes and non-ribosomally ([@B224]; [@B187]; [@B228]). These structurally diverse compounds suppress the growth of competing species and pathogens through different mechanisms primarily connected to membrane permeabilization ([@B57]; [@B176]). Antimicrobial peptides of *Bacilli* were shown to be active against pathogenic bacteria such as *Staphylococcus aureus*, methicillin resistant *S. aureus*, *Clostridium perfringens*, *Klebsiella* sp., and common food spoilage bacteria such as *B. cereus*, *Escherichia coli*, *Listeria monocytogenes, Pseudomonas aeruginosa*, *Aeromonas* sp., *Serratia marcescens*, *Pasteurella haemolytica*, *Salmonella enteritidis*, and *S. gallinarum* ([@B4]; [@B117]; [@B22]; [@B13]; [@B90]; [@B176]; [@B41]; [@B103]; [@B35]; [@B143]). Bacteriocins attract great interest with regard to their potential use as food preservatives ([@B42]; [@B88]) and are regarded as a promising alternative to prevent gastrointestinal infections ([@B49]).

*Lactobacillus* produces a number of bacteriocins usually active against closely related Gram-positive bacteria which are likely to reside in the same ecological niche. Most *Lactobacillus* bacteriocins are small, heat-stable cationic peptides which form pores in the cytoplasmic membrane of sensitive bacteria and thus cause leaking of target cells ([@B137]). Other bacteriocins interrupt production of peptidoglycan or act by interfering with essential enzyme activities in susceptible bacteria ([@B168]). Bacteriocins from *Lactobacillus* are generally recognized as being inactive against Gram-negative organisms. However, it has been reported that bacteriocin from *L. plantarum* TN635 is active against *Salmonella enterica* ATCC43972, *Pseudomonas aeruginosa* ATCC 49189, *Hafnia* sp. and *Serratia* sp. ([@B180]). Moreover, a small bacteriocin (\<6.5 kDa) produced by *L. acidophilus* IBB 801 and designated as acidophilin 801, displayed bactericidal activity against *E. coli* Row and *Salmonella panama* 1467 ([@B225]). Bacteriocin OR-7 produced by *L. salivarius* NRRL B-30514 resulted in reduction of *Campylobacter jejuni* colonization in chicken GI tracts when was added into feed. Interestingly, OR-7 had high sequence similarity to acidocin A, which was previously identified from *L. acidophilus* and had activity only to Gram-positive bacteria ([@B184]).

*Bacillus* is considered to be the second most important bacteriocin producer following lactic acid bacteria which differs from the latter by broad antimicrobial spectrum ([@B1]; [@B13]). Bacteriocins and bacteriocin-like inhibitory substances produced by *Bacillus* exhibit antibacterial activity toward Gram-positive and Gram-negative bacteria as well as fungi, however, activity against Gram-positives is comparatively higher ([@B79]; [@B152]; [@B11]; [@B22]; [@B39]; [@B15]; [@B176]; [@B101]; [@B103]; [@B105]; [@B143]). Species of *Bacillus* differ by their antimicrobial potential ([@B143]). Non-ribosomal peptide antibiotics produced by *Bacillus* (bacitracin, proticin, lichenicidin, bacillaene) are essential for the protection of these bacteria from predation and antibiotics produced by other species ([@B152]; [@B16]; [@B9]; [@B127]). *Bacillus* spp. were shown to produce a mixture of different lipopeptides with antimicrobial activities ([@B78]). *B. subtilis* produces surfactins, fengycins and iturins in a ratio of 6:37:57 ([@B57]; [@B143]). The less abundant surfactins unlike other types of *Bacillus* lipopeptides exhibit a broad range of antimicrobial activities and possess antiviral action ([@B78]). They protect bacilli against extracellular antibiotic-containing vesicles of other species ([@B28]) and inhibit phospholipase A2 resulting in subsequent downregulation of pro-inflammatory cytokines and upregulation of anti-inflammatory cytokines ([@B166]).

Probiotic effect of *B. subtilis* was shown to be connected to **competence and sporulation factor**, a small quorum-sensing peptide involved in bacteria communication, proliferation and sporulation ([@B136]). CSF activates the Akt and p38 MAPK pathways and exerts its anti-inflammatory effect by downregulation of pro-inflammatory mediators (IL-4, IL-6, and CXCL-1), the upregulation of anti-inflammatory IL-10, and the induction of cytoprotective heat shock protein Hsp27 in the intestinal epithelia ([@B136]). The similar effects were observed for two peptides secreted by *B. megaterium* isolated from human ileal biopsies of healthy volunteers ([@B48]). Effects of CSF depend on its uptake by an organic cation transporter-2 in intestine which helps the host to monitor and respond to changes in the behavior or composition of colonic microbiota ([@B60]).

Under-Appreciated Components of *Bacilli* Secretome
===================================================

**Extracellular and surface-associated proteins** secreted by commensal bacteria play an important role in gut colonization and persistence. Moreover, some of them can interact directly with mucosal cells, activating signaling pathways that lead to different cytokine secretion and gene expression profiles ([@B194]). For instance, two secreted proteins p75 and p40 (also known as Msp1 and Msp2) of *L. rhamnosus* GG have been demonstrated to prevent cytokine-induced cell apoptosis by activating the antiapoptotic protein kinase B and by inhibiting the pro-apoptotic MAPK ([@B215]; [@B214]), reduce TNF induced epithelial damage in the colon and as a result promote epithelial homeostasis ([@B214]). Homologs of genes that encode for p40 and p75 were also found in the genomes of *L. casei* and *L. rhamnosus*; the proteins from *L. casei* BL23 were demonstrated to elicit similar host responses ([@B18]).

**Secreted hydrolytic enzymes** contribute to probiotic effects of *Bacilli* due to their ability to decompose food polymers releasing digestive discomfort. However, accumulating data indicate that these proteins might be involved in a complex interaction with host and its microbiota. Hydrolases demonstrate direct antimicrobial activity. Proteases, glycoside hydrolases and DNases participate in dispersal of bacterial biofilms and inhibition of biofilm formation ([@B36]; [@B131]; [@B211]; [@B58]). Extracellular nuclease, NucB, from *B. licheniformis*, was shown to digest extracellular DNA in biofilms of staphylococci and streptococci associated with chronic rhinosinusitis proving enzyme effectiveness in eradicating biofilms of multidrug-resistant bacteria ([@B174]). Secretion of low-molecular-weight guanyl-preferring ribonucleases (RNases) is a distinct feature of some *Bacillus* species ([@B195]). A well-studied representative of these RNases, binase from *B. pumilus*, has manifested antitumor ([@B196]; [@B32]; [@B123]) and antiviral activities ([@B170]; [@B82]; [@B169], [@B171]; [@B126]). KRAS which has mutations in about 40% of patients with colorectal cancer ([@B146]) was shown to be a direct target for antitumor binase ([@B83]). 2′,3′-cGMP generated by binase upon RNA cleavage ([@B182]) may also contribute to modulation of host cells physiology, since it is able to duplicate its counterpart 3′,5′-cGMP ([@B27]) and can exhibit its own regulatory functions. Extracellular cGMP enhances extracellular adenosine and reduces uric acid levels which may render tissue protective effect upon injury ([@B85]). Guanylate cyclase which catalyzes the synthesis of cGMP from GTP is represented in the cell membranes along the intestine. The cGMP signaling regulates intestinal fluid and electrolyte balance, epithelial homeostasis, mucosal barrier integrity, visceral sensation through ERK and AKT pathways ([@B70]; [@B104]; [@B71]; [@B99]). Increased cGMP levels in the colon epithelium activate antioxidant gene expression ([@B210]). cGMP expression is significantly decreased upon ulcerative colitis and colon cancer ([@B104]; [@B99]; [@B141]). cGMP and ways for enhancement of its production are considered for treatment of irritable bowel syndrome by decreasing of gastrointestinal pain and abdominal sensory symptoms ([@B99]) and as a tool for tumor suppression ([@B141]).

Recently, gut *Firmicutes* were shown to produce **peptide aldehydes**, cell-permeable protease inhibitors with a half-life of hours, which target cathepsins in the host lysosome blocking immune recognition of these mutualistic species and enabling them to reside in gut epithelial ([@B67]).

**Nitric oxide** is a well-known ubiquitous molecular mediator produced in mammals by the NOS isoforms at a catalytic site comprising a heme associated with a biopterin cofactor. Genome sequencing has shown the presence of genes encoding for proteins that are highly homologous to the oxygenase domain of mammalian NOS in bacteria, including those of the class *Bacilli*: *S. aureus* ([@B26]; [@B160]), *B. subtilis* ([@B2]), *B. anthracis* ([@B122]; [@B160]), *Geobacillus stearothermophilus* ([@B186]), *L. fermentum* ([@B124]), and *L. plantarum* ([@B3]; [@B81]; [@B80]; [@B220]). So, intestinal *Bacilli* have NOS that is evolutionary related to the mammalian enzymes. Moreover, as bacteria have the most ancient version of NOS, it was hypothesized that Eukaryotes acquired NOS from bacteria by horizontal gene transfer ([@B68]). Recently, the conservation of NOS-derived NO-heme receptor signaling between bacteria and mammals was proved ([@B92]). NO as reactive oxygen molecule is widely considered as important participant in the immune system of different organisms to confront microbial infections. Thus, inhibition of bacterial NOS has the potential to improve the efficacy of antimicrobials used to treat infections by Gram-positive pathogens *S. aureus* and *B. anthracis* possessing this enzyme ([@B76]). Commensal microbiota-derived NO has been shown to influence host physiology. NO synthesized by *L. plantarum* takes part in the regulation of intestinal motility in rat ([@B221]). Being a signaling molecule, NO released by *B. subtilis* in the intestine of *Caenorhabditis elegans* initiates a signaling cascade that results in the induction of 65 genes, including *hsp*s and several other genes that have been implicated in longevity and stress resistance ([@B68]). Involvement of bacterial NO in human cardiovascular system is under investigation ([@B31]).

**Ferrichrome** of *L. casei* was identified as a tumor-suppressive molecule on colon cancer cells which induces apoptosis via activation of c-jun N-terminal kinase (JNK) ([@B93]). Many siderophore-binding proteins were found in EVs of *B. subtilis* ([@B52]; [@B28]). Siderophores can endow bacilli advantage in competition for low-available iron with pathogenic bacteria. Iron cations are potent crosslinkers of the biofilm matrix ([@B37]) and their chelation causes dispersal of biofilms ([@B181]).

Over the last decade, **extracellular vesicles** have emerged as prominent vehicles of biological signals. Intense research on that topic revealed that EVs play important roles in bacterial physiology and pathogenesis, ranging from secretion and delivery of biomolecules (for example, toxins, DNA, or quorum sensing molecules) over stress response and biofilm formation to immunomodulation and adherence to host cells ([@B156]). Both *Bacillus* and *Lactobacillus* species were reported to produce EVs, spherical membranous structures of 20--150 nm in diameter ([@B28], [@B29]; [@B12]; [@B19]; [@B102]). EVs are formed both in planktonic cultures and bacterial biofilms where they help to maintain biofilm cohesion. The quantity of EVs varies with the strain ([@B28]), conditions and stage of growth ([@B91]). Thus, EVs can be produced by Bacilli in GIT.

The EVs are enriched with proteins, lipids, nucleic acids, and metabolites which exhibit biological activities. Release of vesicular cargo is achieved by direct intercellular transfer mediated by the membranes fusion ([@B91]; [@B185]) or by production of special molecules like lipopeptide surfactin which disrupts EVs unspecifically ([@B28]). Therefore, proteins with specific biological activities can be directly delivered inside EVs into other cells ensuring their penetration. In Gram-positive bacteria, proteins secreted via specific pathways are believed to be important for nutrient acquisition, detoxification, competitive survival, and communication ([@B29]). Recent findings support the importance of EVs for interaction of bacteria with each other and the host cells ([@B91]).

Extracellular vesicles carry hydrolytic enzymes for nutrient acquisition from extracellular complex substrates or key nutrients to feed sibling cells and contain specific agents for antagonizing competing species. In EV important for survival compounds are protected from damage retaining activities much longer and can be transported in concentrated amounts for long distances from producing cells. Among these compounds are antibiotics and hydrolytic enzymes including peptidoglycan-degrading hydrolases ([@B118]; [@B10]; [@B185]). EVs isolated from *B. subtilis* contain proteins which are mostly associated with metabolic pathways including biosynthesis of secondary metabolites ([@B28]; [@B91]). Proteins with oxidoreductase and nucleotide binding activities are abundant in vegetative EVs, while proteins with hydrolytic, nucleic acid binding, and structural activity are predominant in sporulating EV ([@B91]). In EVs of sporulating *B. subtilis* superoxide dismutase, alkaline phosphatase III, polyketide synthase PKsM (associated with antibiotic activity) were identified ([@B91]). Sunl protein which confers self-immunity to antibiotic sublancin and many siderophore-binding proteins were found in EVs of *B. subtilis* ([@B52]; [@B28]). The targeted lysis of EVs by surfactin of *B. subtilis* is hypothesized to guard bacilli from alien EVs and disrupt cell signaling by means of EVs in competing populations ([@B185]). EVs were also shown to adsorb phages ([@B25]).

Interaction of EVs with the host is specific to the microorganism from which the EVs were produced and is based on the lipid content and cargo of the EVs ([@B29]). Gram-positive bacterial EVs are composed of various fatty acids which might have a positive effect on host organism ([@B155]). EVs were shown to elicit protective immune response in host ([@B203]). For example, treatment of *C. elegans* with EVs originated from *L. plantarum* WCFS1 led to increased transcription of host defense genes, *cpr-1* and *clec-60*, and thus provided protection against vancomycin-resistant *Enterococcus faecium*. Moreover, in human Caco-2 cells these EVs had similar effect, leading to the upregulation of *REG3G*, which is functionally similar to *clec-60*, and *CTSB*, the human ortholog of *cpr-1* ([@B102]). The EVs from *B. lentus* isolated from Korean soybean fermented food induced apoptosis of human colon carcinoma cells HCT116 ([@B217]). EVs derived from *L. rhamnosus* GG are likely to be implicated in the anti-cancer activity as they induce apoptosis in the hepatic adenocarcinoma cell line HepG2 via augmentation of the expression ratio between pro- and anti-apoptotic genes *bax/bcl-2* ([@B19]).

Conclusion and Further Perspectives
===================================

Now, it has become clear that studies on phylotype profiling are limited to the identification of microbial constituents, where information is lacking about the molecular interaction of bacterial communities with the host. Lactobacilli are well-represented in the human GIT and secrete a number of compounds which have direct and indirect effects on the health of GIT and organism as a whole. Species of *Bacillus* genus are much less abundant but are capable of producing several times more extracellular molecules than lactobacilli. Many of them still require exploration. Further deep studies are needed for better understanding of the complex interactions between human organism and its microbiota, clarification of the particular mechanisms underlying remarkable beneficial properties of probiotic *Bacilli*, and the specific action of innumerous secreted low- and high-molecular weight compounds and their vesicular transportation.
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